Developer docs
API playgroundTry for free, no card

Search company profiles

Bharat Biotech

Full company profile

uuid0002s24

Namestring
Bharat Biotech
Legal namestring
Bharat Biotech International Limited
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Bharat Biotech International Limited, founded in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra Ella, is a Hyderabad-headquartered, entirely promoter-owned biotechnology company that develops and manufactures vaccines and bio-therapeutics. It operates one of India's most comprehensive vaccine portfolios with over 20 vaccines spanning COVID-19 (COVAXIN, iNCOVACC), rotavirus (ROTAVAC, ROTAVAC 5D), typhoid (Typbar TCV, Typbar), cholera (Hillchol), Japanese encephalitis (JENVAC), rabies (Indirab), polio (Biopolio), Hib (BioHib), and combination pediatric products (Comvac 4/5), plus biotherapeutic wound-healing brands (REGEN-D, SLVRGEN). The company's technology stack spans five vaccine platforms: inactivated whole virion, live attenuated, polysaccharide conjugate, recombinant DNA, and viral vector, anchored by proprietary HIMAX technology for cesium chloride-free Hepatitis B and a BSL-3 high-containment facility at Genome Valley that produced COVAXIN at 77.8% efficacy. As of July 2025 the company holds 220+ granted global patents with 415 filings, 9-10 billion cumulative doses delivered, manufacturing across six Indian sites, and active distribution to 125+ countries.

Short descriptiontext

Bharat Biotech is a Hyderabad-based, promoter-owned biotechnology company founded in 1996 that develops and manufactures a portfolio of 20+ vaccines and biotherapeutics across five proprietary technology platforms for governments, WHO/UNICEF, and private markets in 125+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccines manufacturing, biotherapeutics production, cell and gene therapy, immunization products, recombinant vaccines
Industry5 codes
PRIMARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAJAG
Vaccines & Cold-Chain Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Vaccines & Biotherapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Vaccine Product Sales
TypeOne Time License
Description

Sale of vaccines including COVAXIN, ROTAVAC, Typbar TCV, and other vaccine products to government immunization programs and private markets globally

zeenews.india.com
2Biotherapeutic Products
TypeOne Time License
Description

Sale of biotherapeutic products including REGEN-D for diabetic foot ulcers and burns, and SLVRGEN for wound healing

bharatbiotech.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary technologies and manufacturing capabilities to international partners

zeenews.india.com
4CRDMO Services
TypeProfessional Services
Description

Contract research, development and manufacturing services through Nucelion Therapeutics for cell and gene therapies

zeenews.india.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1COVID-19 intranasal vaccine iNCOVACC pricing tiers
ModelUnit PricingBilling cadencePay-as-you-go
Notes

INR 800+GST for private markets, INR 325+GST for government programs

zeenews.india.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1COVAXIN
Description

India's first indigenous COVID-19 vaccine, developed in collaboration with ICMR-NIV

bharatbiotech.com
+8 more records
Core offering1 text field

Bharat Biotech manufactures and supplies a portfolio of 20+ vaccines and biotherapeutic products, including COVID-19 vaccines (COVAXIN, iNCOVACC), rotavirus vaccines (ROTAVAC, ROTAVAC 5D), typhoid conjugate vaccine (Typbar TCV), cholera vaccine (Hillchol), rabies, polio, Japanese encephalitis, Hib, hepatitis B, and combination pediatric vaccines, along with wound-healing biotherapeutics (REGEN-D, SLVRGEN). The company also operates a CRDMO subsidiary (Nucelion Therapeutics) providing cell and gene therapy contract manufacturing services. Products are sold to government immunization programs and private healthcare markets across 125+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ROTAVAC 5D reduces moderate-to-severe rotavirus diarrhoea hospitalizations in children under five from 36% to 18%
+2 more records
Product overview1 text field

Bharat Biotech is a Hyderabad-based vaccine and biotherapeutics manufacturer established in 1996, operating as a comprehensive product portfolio company with over 20 vaccines and 4 biotherapeutics. The company's vaccine portfolio spans major disease areas including COVID-19 (COVAXIN®, iNCOVACC®), rotavirus (ROTAVAC®, ROTAVAC 5D®), typhoid (Typbar TCV®, Typbar®), cholera (Hillchol®), Japanese encephalitis (JENVAC®), influenza (HNVAC®), rabies (Indirab®), polio (Biopolio®), Hib (BioHib®), and combination pediatric vaccines (Comvac 4®, Comvac 5®). The hepatitis B franchise includes Revac-B mcf® and Revac-B+® using proprietary HIMAX technology. Biotherapeutics include REGEN-D® 150 and 60 (epidermal growth factors for wound healing), SLVRGEN® (burns treatment), and BIOGIT® (probiotic yeast). The company has expanded into cell and gene therapies through its Nucelion Therapeutics subsidiary, representing a post-pandemic strategic pivot. Bharat Biotech delivers approximately 9-10 billion vaccine doses annually to over 125 countries, with manufacturing facilities in Hyderabad, Ankleshwar, Mallur, and Pune, all conforming to USFDA, KFDA, WHO, and other global regulatory standards.

Product and service21 records
1COVAXIN
CategoryVaccine
2iNCOVACC (BBV154)
CategoryVaccine
3ROTAVAC
CategoryVaccine
4ROTAVAC 5D
CategoryVaccine
5Typbar TCV
CategoryVaccine
6Typbar
CategoryVaccine
7Hillchol
CategoryVaccine
8JENVAC
CategoryVaccine
9HNVAC
CategoryVaccine
10Indirab
CategoryVaccine
11Biopolio
CategoryVaccine
12BioHib
CategoryVaccine
13Comvac 5
CategoryVaccine
14Comvac 4
CategoryVaccine
15Revac-B mcf
CategoryVaccine
16Revac-B+
CategoryVaccine
17SLVRGEN
CategoryTherapeutic
18REGEN-D 150
CategoryTherapeutic
19REGEN-D 60
CategoryTherapeutic
20BIOGIT
CategoryTherapeutic
21Nucelion Therapeutics (CRDMO Services)
CategorySubsidiary/CRDMO Services
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

Key partnership for AI-driven plant genomics targeting sustainable agriculture solutions

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Bharat Biotech emerged as a key investor supporting maritime innovation project in Andhra Pradesh

3Sapigen Biologix Pvt Ltd
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-27
Description

Subsidiary developing large vaccine manufacturing facility in Bhubaneswar, Odisha with Rs 200-250 crore investment

zeenews.india.com
4Tamil Nadu Government
Strategic tierCoreTypeOthersAnnounced on2026-02-12
Description

MoU signed for ₹5,000 crore bio-similars manufacturing facility in Kancheepuram district; government facilitating life sciences park development

outlookbusiness.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

Collaboration with Nucelion Therapeutics (Bharat Biotech subsidiary) to expand manufacturing capabilities for exosome-based therapeutic platform targeting ocular diseases across Asia-Pacific region

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-22
Description

Technology transfer agreement for MTBVAC tuberculosis vaccine to support manufacturing and distribution in over 70 countries as part of India's Phase III clinical trial preparations expected to start in early 2026

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-27
Description

Partnership for launch of Hillchol oral cholera vaccine in India with plans for WHO prequalification for global distribution

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-11
Description

Collaboration for development and commercialization of broad-spectrum anti-microbial vaccine AV0328

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-12
Description

Partnership to advance development of GSK's Shigella vaccine candidate for severe bacterial diarrhoea; also malaria vaccine RTS,S supply partnership

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-23
Description

Licensing deal for intranasal COVID-19 vaccine technology advancement

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-10
Description

CEPI-funded partnership to develop 'variant-proof' COVID-19 vaccine

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-02
Description

Collaboration to produce and supply Oral Polio Vaccines leveraging combined manufacturing capabilities

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-03-16
Description

Co-development and commercialization of COVAXIN for US market; expanded to include Canada

14Precisa Medicamentos
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-02-12
Description

Supply agreement for COVAXIN to Brazil

bharatbiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-27
Description

Product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-03
Description

CEPI grant of US$14.1 million for Chikungunya vaccine development in collaboration with Ind-CEPI

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

US-based biopharmaceutical partner commercializing COVAXIN in the United States and Canada. Channel partner relationship rather than direct competitor, but provides a useful comparable for routes-to-market in regulated Western geographies.

2Biological E
TypeDirect peer
Description

Hyderabad-based Indian vaccine and biologic manufacturer with strong pediatric immunization portfolio including Japanese encephalitis, DPT, and pentavalent vaccines. Comparable as a peer Indian vaccine producer targeting government tenders and emerging-market supply through WHO PQ.

TypeDirect peer
Description

New Delhi-based Indian vaccine manufacturer with WHO-prequalified products across polio, DPT, and combination pediatric vaccines. Direct competitor for Indian government immunization contracts and emerging-market tenders with overlapping product portfolio.

TypeBroad incumbent
Description

Global vaccine major with established portfolio across pediatric, travel, and adult vaccines including Shigella and RTS,S malaria — both of which are partnered with Bharat Biotech. Broad incumbent serving overlapping disease areas but with much wider geographic and product reach.

TypeDirect peer
Description

Hyderabad-based Indian vaccine manufacturer (National Dairy Development Board subsidiary) producing rabies, pediatric, and animal vaccines. Direct peer in Indian government immunization supply and rabies market where Bharat Biotech's Indirab competes.

6Sinovac Biotech
TypeEmerging player
Description

Chinese vaccine manufacturer with WHO-prequalified COVID-19, influenza, and hepatitis vaccines targeting emerging markets. Comparable as an emerging-market vaccine producer competing for WHO PQ supply positions and developing-world immunization tenders.

TypeEmerging player
Description

Singapore-based vaccine developer co-founded by MSD and Wellcome Trust, partnering with Bharat Biotech on Hillchol oral cholera vaccine. Niche player focused on affordable vaccines for developing countries, with overlapping tropical-disease R&D priorities.

TypeDirect peer
Description

World's largest vaccine manufacturer by doses, headquartered in Pune, India. Direct competitor across polio, rotavirus, HPV, measles, and pandemic vaccines, supplying UNICEF and GAVI at global scale. Bharat Biotech and SII compete head-to-head for Indian government immunization contracts and WHO PQ supply positions.

9Sanofi Pasteur
TypeBroad incumbent
Description

Global vaccines division of Sanofi with deep portfolio across pediatric (Hexaxim), influenza, travel, and rabies vaccines. Broader incumbent competitor in higher-margin travel and adult segments; co-markets Shanchol oral cholera vaccine in markets where Bharat Biotech's Hillchol competes.

TypeEmerging player
Description

Spanish biopharmaceutical manufacturer that developed MTBVAC tuberculosis vaccine and signed a technology transfer agreement with Bharat Biotech for manufacturing and distribution in 70+ countries. Specialized vaccine developer with overlapping TB pipeline focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bharat Biotech

Vaccines & Biotherapeuticsbharatbiotech.com

Bharat Biotech is a Hyderabad-based, promoter-owned biotechnology company founded in 1996 that develops and manufactures a portfolio of 20+ vaccines and biotherapeutics across five proprietary technology platforms for governments, WHO/UNICEF, and private markets in 125+ countries.

What Bharat Biotech does

Bharat Biotech International Limited, founded in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra Ella, is a Hyderabad-headquartered, entirely promoter-owned biotechnology company that develops and manufactures vaccines and bio-therapeutics. It operates one of India's most comprehensive vaccine portfolios with over 20 vaccines spanning COVID-19 (COVAXIN, iNCOVACC), rotavirus (ROTAVAC, ROTAVAC 5D), typhoid (Typbar TCV, Typbar), cholera (Hillchol), Japanese encephalitis (JENVAC), rabies (Indirab), polio (Biopolio), Hib (BioHib), and combination pediatric products (Comvac 4/5), plus biotherapeutic wound-healing brands (REGEN-D, SLVRGEN). The company's technology stack spans five vaccine platforms: inactivated whole virion, live attenuated, polysaccharide conjugate, recombinant DNA, and viral vector, anchored by proprietary HIMAX technology for cesium chloride-free Hepatitis B and a BSL-3 high-containment facility at Genome Valley that produced COVAXIN at 77.8% efficacy. As of July 2025 the company holds 220+ granted global patents with 415 filings, 9-10 billion cumulative doses delivered, manufacturing across six Indian sites, and active distribution to 125+ countries.

Bharat Biotech firmographics

Firmographics
Name
Bharat Biotech
Legal name
Bharat Biotech International Limited
Website
https://bharatbiotech.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Bharat Biotech is a Hyderabad-based, promoter-owned biotechnology company founded in 1996 that develops and manufactures a portfolio of 20+ vaccines and biotherapeutics across five proprietary technology platforms for governments, WHO/UNICEF, and private markets in 125+ countries.
Ownership category
akta.pro rank

Bharat Biotech industry classification

Industry
Product category
Vaccines & Biotherapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAEAE
Travel & Tropical Disease Vaccines
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAJAG
Vaccines & Cold-Chain Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Vaccines manufacturing
  • Biotherapeutics production
  • Cell and gene therapy
  • Immunization products
  • Recombinant vaccines

Where Bharat Biotech is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices7 records

Markets served

Bharat Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Vaccine Product Sales: Sale of vaccines including COVAXIN, ROTAVAC, Typbar TCV, and other vaccine products to government immunization programs and private markets globally
  2. Biotherapeutic Products: Sale of biotherapeutic products including REGEN-D for diabetic foot ulcers and burns, and SLVRGEN for wound healing
  3. Technology Licensing: Licensing of proprietary technologies and manufacturing capabilities to international partners
  4. CRDMO Services: Contract research, development and manufacturing services through Nucelion Therapeutics for cell and gene therapies

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCOVID-19 intranasal vaccine iNCOVACC pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Bharat Biotech product offering

Product offering

Core offering

Bharat Biotech manufactures and supplies a portfolio of 20+ vaccines and biotherapeutic products, including COVID-19 vaccines (COVAXIN, iNCOVACC), rotavirus vaccines (ROTAVAC, ROTAVAC 5D), typhoid conjugate vaccine (Typbar TCV), cholera vaccine (Hillchol), rabies, polio, Japanese encephalitis, Hib, hepatitis B, and combination pediatric vaccines, along with wound-healing biotherapeutics (REGEN-D, SLVRGEN). The company also operates a CRDMO subsidiary (Nucelion Therapeutics) providing cell and gene therapy contract manufacturing services. Products are sold to government immunization programs and private healthcare markets across 125+ countries.

Product overview

Bharat Biotech is a Hyderabad-based vaccine and biotherapeutics manufacturer established in 1996, operating as a comprehensive product portfolio company with over 20 vaccines and 4 biotherapeutics. The company's vaccine portfolio spans major disease areas including COVID-19 (COVAXIN®, iNCOVACC®), rotavirus (ROTAVAC®, ROTAVAC 5D®), typhoid (Typbar TCV®, Typbar®), cholera (Hillchol®), Japanese encephalitis (JENVAC®), influenza (HNVAC®), rabies (Indirab®), polio (Biopolio®), Hib (BioHib®), and combination pediatric vaccines (Comvac 4®, Comvac 5®). The hepatitis B franchise includes Revac-B mcf® and Revac-B+® using proprietary HIMAX technology. Biotherapeutics include REGEN-D® 150 and 60 (epidermal growth factors for wound healing), SLVRGEN® (burns treatment), and BIOGIT® (probiotic yeast). The company has expanded into cell and gene therapies through its Nucelion Therapeutics subsidiary, representing a post-pandemic strategic pivot. Bharat Biotech delivers approximately 9-10 billion vaccine doses annually to over 125 countries, with manufacturing facilities in Hyderabad, Ankleshwar, Mallur, and Pune, all conforming to USFDA, KFDA, WHO, and other global regulatory standards.

Differentiator

Problem solved

Functional benefit

Brands

  • COVAXIN: India's first indigenous COVID-19 vaccine, developed in collaboration with ICMR-NIV
  • iNCOVACC
  • ROTAVAC
  • ROTAVAC 5D
  • Typbar TCV
  • Hillchol
  • JENVAC
  • REGEN-D
  • Nucelion Therapeutics

Products and services

  • COVAXIN
  • iNCOVACC (BBV154)
  • ROTAVAC
  • ROTAVAC 5D
  • Typbar TCV
  • Typbar
  • Hillchol
  • JENVAC
  • HNVAC
  • Indirab
  • Biopolio
  • BioHib
  • Comvac 5
  • Comvac 4
  • Revac-B mcf
  • Revac-B+
  • SLVRGEN
  • REGEN-D 150
  • REGEN-D 60
  • BIOGIT
  • Nucelion Therapeutics (CRDMO Services)

Quantifiable outcome

  • ROTAVAC 5D reduces moderate-to-severe rotavirus diarrhoea hospitalizations in children under five from 36% to 18%
  • +2 more outcomes

Companies that use Bharat Biotech

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Bharat Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Bharat Biotech partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered minor and core.

  • Evogene LtdminorStrategic or Co-development Partner · 2 April 2026Key partnership for AI-driven plant genomics targeting sustainable agriculture solutions
  • Sagar Defence Engineering Pvt LtdminorStrategic or Co-development Partner · 12 March 2026Bharat Biotech emerged as a key investor supporting maritime innovation project in Andhra Pradesh
  • Sapigen Biologix Pvt LtdcoreStrategic or Co-development Partner · 27 February 2026Subsidiary developing large vaccine manufacturing facility in Bhubaneswar, Odisha with Rs 200-250 crore investment
  • Tamil Nadu GovernmentcoreOthers · 12 February 2026MoU signed for ₹5,000 crore bio-similars manufacturing facility in Kancheepuram district; government facilitating life sciences park development
  • Pandorum TechnologiescoreStrategic or Co-development Partner · 6 January 2026Collaboration with Nucelion Therapeutics (Bharat Biotech subsidiary) to expand manufacturing capabilities for exosome-based therapeutic platform targeting ocular diseases across Asia-Pacific region
  • BiofabricoreStrategic or Co-development Partner · 22 December 2025Technology transfer agreement for MTBVAC tuberculosis vaccine to support manufacturing and distribution in over 70 countries as part of India's Phase III clinical trial preparations expected to start in early 2026
  • Hilleman LaboratoriescoreStrategic or Co-development Partner · 27 August 2025Partnership for launch of Hillchol oral cholera vaccine in India with plans for WHO prequalification for global distribution
  • AlopexxcoreStrategic or Co-development Partner · 11 September 2024Collaboration for development and commercialization of broad-spectrum anti-microbial vaccine AV0328
  • GSKcoreStrategic or Co-development Partner · 12 June 2024Partnership to advance development of GSK's Shigella vaccine candidate for severe bacterial diarrhoea; also malaria vaccine RTS,S supply partnership
  • Washington University School of MedicinecoreStrategic or Co-development Partner · 23 September 2022Licensing deal for intranasal COVID-19 vaccine technology advancement
  • University of Sydney and ExcellGenecoreStrategic or Co-development Partner · 10 May 2022CEPI-funded partnership to develop 'variant-proof' COVID-19 vaccine
  • Bilthoven Biologicals (Serum Institute)coreStrategic or Co-development Partner · 2 April 2022Collaboration to produce and supply Oral Polio Vaccines leveraging combined manufacturing capabilities
  • OcugencoreChannel Partner/ Reseller/ Distributor · 16 March 2022Co-development and commercialization of COVAXIN for US market; expanded to include Canada
  • Precisa MedicamentoscoreChannel Partner/ Reseller/ Distributor · 12 February 2021Supply agreement for COVAXIN to Brazil
  • GSK, PATHcoreStrategic or Co-development Partner · 27 January 2021Product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
  • CEPI and IVIcoreStrategic or Co-development Partner · 3 June 2020CEPI grant of US$14.1 million for Chikungunya vaccine development in collaboration with Ind-CEPI

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

Bharat Biotech competitors and assessment

Company assessment

Others

  • Ocugen: US-based biopharmaceutical partner commercializing COVAXIN in the United States and Canada. Channel partner relationship rather than direct competitor, but provides a useful comparable for routes-to-market in regulated Western geographies.

Direct peers

  • Biological E: Hyderabad-based Indian vaccine and biologic manufacturer with strong pediatric immunization portfolio including Japanese encephalitis, DPT, and pentavalent vaccines. Comparable as a peer Indian vaccine producer targeting government tenders and emerging-market supply through WHO PQ.
  • Panacea Biotec: New Delhi-based Indian vaccine manufacturer with WHO-prequalified products across polio, DPT, and combination pediatric vaccines. Direct competitor for Indian government immunization contracts and emerging-market tenders with overlapping product portfolio.
  • Indian Immunologicals: Hyderabad-based Indian vaccine manufacturer (National Dairy Development Board subsidiary) producing rabies, pediatric, and animal vaccines. Direct peer in Indian government immunization supply and rabies market where Bharat Biotech's Indirab competes.
  • Serum Institute of India: World's largest vaccine manufacturer by doses, headquartered in Pune, India. Direct competitor across polio, rotavirus, HPV, measles, and pandemic vaccines, supplying UNICEF and GAVI at global scale. Bharat Biotech and SII compete head-to-head for Indian government immunization contracts and WHO PQ supply positions.

Broad incumbents

  • GSK: Global vaccine major with established portfolio across pediatric, travel, and adult vaccines including Shigella and RTS,S malaria — both of which are partnered with Bharat Biotech. Broad incumbent serving overlapping disease areas but with much wider geographic and product reach.
  • Sanofi Pasteur: Global vaccines division of Sanofi with deep portfolio across pediatric (Hexaxim), influenza, travel, and rabies vaccines. Broader incumbent competitor in higher-margin travel and adult segments; co-markets Shanchol oral cholera vaccine in markets where Bharat Biotech's Hillchol competes.

Emerging players

  • Sinovac Biotech: Chinese vaccine manufacturer with WHO-prequalified COVID-19, influenza, and hepatitis vaccines targeting emerging markets. Comparable as an emerging-market vaccine producer competing for WHO PQ supply positions and developing-world immunization tenders.
  • Hilleman Laboratories: Singapore-based vaccine developer co-founded by MSD and Wellcome Trust, partnering with Bharat Biotech on Hillchol oral cholera vaccine. Niche player focused on affordable vaccines for developing countries, with overlapping tropical-disease R&D priorities.
  • Biofabri: Spanish biopharmaceutical manufacturer that developed MTBVAC tuberculosis vaccine and signed a technology transfer agreement with Bharat Biotech for manufacturing and distribution in 70+ countries. Specialized vaccine developer with overlapping TB pipeline focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Bharat Biotech social profiles

Digital presence

Bharat Biotech compliance and trust

Trust signal

Compliance8 records

Bharat Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bharat Biotech leadership team

Management profile

Number of profiles

Profiles6 records

Bharat Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Bharat Biotech funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bharat Biotech M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bharat Biotech

What does Bharat Biotech do?

Bharat Biotech manufactures and supplies a portfolio of 20+ vaccines and biotherapeutic products, including COVID-19 vaccines (COVAXIN, iNCOVACC), rotavirus vaccines (ROTAVAC, ROTAVAC 5D), typhoid conjugate vaccine (Typbar TCV), cholera vaccine (Hillchol), rabies, polio, Japanese encephalitis, Hib, hepatitis B, and combination pediatric vaccines, along with wound-healing biotherapeutics (REGEN-D, SLVRGEN). The company also operates a CRDMO subsidiary (Nucelion Therapeutics) providing cell and gene therapy contract manufacturing services. Products are sold to government immunization programs and private healthcare markets across 125+ countries.

Is Bharat Biotech a public or private company?

Bharat Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Bharat Biotech founded?

Bharat Biotech was founded in 1996. It employs 1,001 to 5,000 people.

Where is Bharat Biotech based?

Bharat Biotech is headquartered in Hyderabad, India, in the Asia region.

How does Bharat Biotech make money?

Four revenue lines are on record. Vaccine Product Sales are the primary driver. The others are biotherapeutic Products, technology Licensing and CRDMO Services.

Who are Bharat Biotech's main competitors?

Ocugen is listed as an others. Direct peers are Biological E, Panacea Biotec, Indian Immunologicals and Serum Institute of India. Broad incumbents are GSK and Sanofi Pasteur. Emerging players are Sinovac Biotech, Hilleman Laboratories and Biofabri.

Does Bharat Biotech have an API?

No public API is recorded for Bharat Biotech.

What industry is Bharat Biotech in?

Bharat Biotech's product category is Vaccines & Biotherapeutics. Its primary akta.pro industry code is HLAIAEAE, Travel & Tropical Disease Vaccines, with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaPharma Heirs Trade Safe Bets for Scientific AmbitionSecond-generation heirs at India's family-run pharma firms are taking on leadership roles and steering companies toward complex generics, peptides, and advanced therapeutics. Laurus Labs' CDMO revenue rose 36% in 2025-26, and Bharat Biotech is moving beyond vaccines. The shift requires deep technical capabilities and carries uncertain returns.The Times of IndiaMore than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger rolesNext-generation leaders at Indian pharma firms are driving strategic shifts into complex generics, peptides, and advanced therapeutics. Laurus Labs' CDMO revenue rose 36% in 2025-26, and Bharat Biotech is moving beyond vaccines. These moves involve long-term capital investments with uncertain returns.BusinessLineBharat Biotech slashes price of malaria vaccine MOSQIVAC by 40%Bharat Biotech announced a nearly 40% price cut on its malaria vaccine MOSQIVAC, developed by GSK. The reduction, backed by Gavi and UNICEF, will protect an additional 1 million children and generate $50 million in savings. The company cited the urgent need, noting one child dies from malaria every minute.WhalesbookBharat Biotech Slashes Malaria Vaccine Price 40% in Gavi DealBharat Biotech will cut its malaria vaccine price by 40% to EUR 5.50 per dose starting early 2027, in a Gavi-UNICEF deal. The move, backed by a $200 million manufacturing expansion, is projected to save immunization programs $50 million through 2029. The company aims to vaccinate 50 million children by 2030.Business & FinancialBharat Biotech And Gavi Announce 40 Percent Price Cut For Malaria VaccineBharat Biotech and Gavi announced a 40% price cut for the malaria vaccine RTS, S/AS01, bringing the price to EUR 5.50 per dose. The deal, backed by Gavi and UNICEF, will save about $50 million in immunization programs between 2027 and 2029 and reach up to one million more children.The Times of IndiaBharat Biotech slashes price of malaria vaccine MOSQIVAC by 40%Bharat Biotech announced a nearly 40% price cut on its malaria vaccine MOSQIVAC, developed by GSK. The reduction, backed by UNICEF and Gavi, will protect an additional 1 million children and generate $50 million in savings. The company cited the urgent need, noting one child dies from malaria every minute.The Times of IndiaBharat Biotech is 'back in action' after Covid reset: Krishna Ella on TB vaccine, Nipah-Ebola shots, gene therapy, IPO plans & what’s nextKrishna Ella said Bharat Biotech has reset after a two-year Covid pause and is back in action. The company, a 100% vaccines firm, is expanding into cell and gene therapy and monoclonal antibodies, with TB vaccine Phase 2 complete and Phase 3 pending. He is considering an IPO to fund new therapies.AInvestTTD Offers Rs 2 Lakh Insurance to Devotees, CM Naidu Announces Temple Development PlansTirumala Tirupati Devasthanams (TTD) partnered with LIC to offer Rs 2 lakh insurance to devotees in case of death during a temple visit. Andhra Pradesh Chief Minister Naidu announced temple development plans, including construction via Srivani Trust and a healing center, with donations from Reliance Foundation and Bharat Biotech.The HinduChandrababu Naidu inaugurates Pilgrim Experience Centre, SV Museum; flags off 32 electric buses at TirumalaAndhra Pradesh Chief Minister N. Chandrababu Naidu inaugurated a Pilgrim Experience Centre and the SV Museum in Tirumala, and flagged off 32 electric buses. The centre, costing ₹4 crore, offers 3D videos and VR darshan, while the buses are provided by Reliance Foundation and Bharat Biotech.Deccan Chronicle15 Eelectric Buses Donated by Anant Ambani Reaches TirumalaFifteen electric buses donated by Anant Ambani reached Tirumala on Sunday morning. The donation, worth Rs 27.5 crore, includes 25 buses, 50 drivers, and charging stations, with inauguration scheduled for September 16. Seven more buses from Bharat Biotech are also expected to arrive.